… therapies for lung cancer as well as other solid tumors using a molecular targeted approach
but our progress in treating pancreatic cancer … urgent need for improved therapies with better …

… with FOLFIRINOX among patients with metastatic pancreatic cancer, 12 we anticipated that
… therapy, which would correspond to a hazard ratio for cancer-related event, second cancer, …

… therapies are usually more effective than monotherapies. We propose that effective combination
therapies for pancreatic cancer … lesions common to pancreatic tumors and that synergize …

… to chemoradiotherapy alone for resectable pancreatic cancer (1 year-survival … therapy option
where possible. Standard oncological resections for pancreatic cancer consist of pancreatic …

… with pancreatic cancer has been ascribed to both the aggressive biological nature of PDA
and to the ineffectiveness of systemic therapies … patients with pancreatic cancer who undergo …

… Distinct molecular and biological responses to different types of therapies need to be better
… therapies by integrating the fundamental clinical and molecular features of the cancer. …

… pancreatic cancer treatments, including those for patients with metastatic, locally advanced
and borderline resectable pancreatic cancer, … current and future pancreatic cancer therapies. …

… of pancreatic cancer biology and ability to perform more complex pancreatic cancer surgeries
… We review the major advances in pancreatic cancer therapy during the last 5 years, and …

… Pancreatic cancer is a lethal disease and currently available therapies have significant
limitations. Pancreatic cancer is thus an ideal setting for the development of novel treatment …

… emerged soon thereafter and fuelled great enthusiasm in the pancreas cancer community.21 …
in pancreatic cancer with potential implications for future therapy and clinical trial design. …